Navigation Links
Venture Capital Veteran John Brooks Joins Life Science Investment Bank Johnston Blakely & Company
Date:5/4/2009

BOSTON, May 4 /PRNewswire/ -- Johnston Blakely & Company, LLC, a Boston-based life science investment bank, is pleased to announce that John L. Brooks, III has joined the firm as senior advisor. In this role, Mr. Brooks will participate with the firm on internal and client-related activities including private equity placements and merger & acquisition advisory services, with a particular focus on medical device transactions. "We are thrilled to welcome John Brooks to the Johnston Blakely family," remarked Johnston Blakely founder Benjamin Conway. "Not only does John bring to the firm and its clients a track record of success in both venture capital and the medical device industry, but his decision to join us is also a strong endorsement of Johnston Blakely and its capabilities."

John Brooks co-founded the venture capital firm Prism Venture Partners. During his ten-year tenure with Prism, the firm raised $1.25 billion across six venture funds. While with Prism, Mr. Brooks led the firm's healthcare investment activities including its role in the creation of companies such as Insulet Corporation. His previous experience also includes senior management positions at Pfizer, both with Pfizer/Valleylab as General Manager and with Pfizer/Strato. Mr. Brooks has held several vice president of finance and operations positions at successful venture-backed companies and spent over 10 years in public accounting and consulting focused on supporting venture backed entrepreneurs.

In addition to his current involvement on the boards of certain Prism portfolio companies, John Brooks is vice chairman of the Board of Trustees of the Joslin Diabetes Center where he is also chairman of the finance committee, a member of the steering committee of Mass Medic's MedTech Ignite (Inspiring Growth in New Innovative Technology Enterprises) program and is on the Draper BioAdvisory Board.

About Johnston Blakely & Company

Johnston Blakely & Company, LLC is a Boston-based investment bank offering private equity placement and merger & acquisition-related financial advisory services to companies in the life science sector. The firm incorporates the venture capital tradition of comprehensive company involvement into investment banking engagements to deliver superior results for its clients. More than investment banking...inVenture banking(TM).

Johnston Blakely is a registered broker/dealer and member of FINRA/SIPC.


'/>"/>
SOURCE Johnston Blakely & Company, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. UMass Boston Opens Venture Development Center to Expand R&D Activity
2. Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities
3. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
4. CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture
5. NexGen Biofuels Ltd Signs Letter of Intent for the Purchase of World Venture Management, Inc. Assets and the Sale of its Current Business
6. Cynvec to Present at the BIO National Venture Conference
7. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
8. Merck Serono Launches Strategic Venture Capital Fund
9. StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies
10. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
11. Alltech, Mitsui and Asahi Breweries Create New Venture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. (OTCQB: ... focused on developing and commercializing products to treat rare ... today that it will be hosting an Investor Webcast ... on the origins of innate defense regulators (IDRs) as ... of oral mucositis and the recently announced and published ...
(Date:12/8/2016)... Dec. 8, 2016 Savannah River Remediation ... and selected NewTechBio,s NT-MAX Lake & Pond ... beneficial bacteria, in conjunction with Hexa Armor/ Rhombo ... with National Pollutant Discharge Elimination System requirements. ... a steady history of elevated pH levels, above ...
(Date:12/8/2016)... , Dec. 8, 2016  Partnering to fuel ... Ben Franklin Technology Partners of Southeastern Pennsylvania ... ("IHG"), the parent company of Independence Blue Cross; and ... announced their intentions for a $6 million funding initiative ... healthcare startups. Responding to a burgeoning economic ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... I/II dose escalation and expansion clinical trial for its lead drug candidate, AC0010, ... purpose of the trial was to determine the safety, antitumor activity, and recommended ...
Breaking Biology Technology:
(Date:12/7/2016)...   Veridium , a leader in biometrics-based ... CEO James Stickland . Stickland, a seasoned ... has served in senior executive roles for HSBC, ... expanding a pipeline of venture capital and accelerating ... served as managing director of U.K.-based fintech firm ...
(Date:12/5/2016)...  The Office of Justice Programs, National Institute ... Enhance or Replace Medico Legal Autopsies?" on NIJ.gov.  ... replacing forensic autopsies with postmortem X-ray computed tomography, ... response to recommendations made by The National Academy ... as a potential component of medicolegal death investigations. ...
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
Breaking Biology News(10 mins):